000181140 001__ 181140
000181140 005__ 20240229145641.0
000181140 0247_ $$2doi$$a10.1007/s00432-022-04277-7
000181140 0247_ $$2pmid$$apmid:35963900
000181140 0247_ $$2ISSN$$a0084-5353
000181140 0247_ $$2ISSN$$a0171-5216
000181140 0247_ $$2ISSN$$a0943-9382
000181140 0247_ $$2ISSN$$a1432-1335
000181140 0247_ $$2altmetric$$aaltmetric:140491594
000181140 037__ $$aDKFZ-2022-01793
000181140 041__ $$aEnglish
000181140 082__ $$a610
000181140 1001_ $$00000-0002-4015-1466$$aStruckmeier, Ann-Kristin$$b0
000181140 245__ $$aIDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma.
000181140 260__ $$aBerlin$$bSpringer$$c2023
000181140 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2022-08-13
000181140 3367_ $$2DRIVER$$aarticle
000181140 3367_ $$2DataCite$$aOutput Types/Journal article
000181140 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688562156_17043
000181140 3367_ $$2BibTeX$$aARTICLE
000181140 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181140 3367_ $$00$$2EndNote$$aJournal Article
000181140 500__ $$a2023 Jul;149(7):3623-3635
000181140 520__ $$aStrategies for Indolamine-2,3-dioxygenase 1 (IDO1) inhibition in cancer immunotherapy once produced encouraging results, but failed in clinical trials. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance.In this study, we investigated the significance of IDO1 expressing immune cells in primary tumours and corresponding lymph node metastases (LNMs) in oral squamous cell carcinoma (OSCC) by immunohistochemistry. The link between IDO1 and macrophages was investigated by flow cytometry in tumour tissue, healthy adjacent tissue and peripheral blood mononuclear cells (PBMCs). IDO1 activity (measured as Kynurenine/Tryptophan ratio) was assessed by ELISAs.High IDO1 expression in tumour-infiltrating immune cells was significantly correlated with advanced stages [Spearman's rank correlation (SRC), p = 0.027] and reduced progression-free survival (multivariate Cox regression, p = 0.034). IDO1 was significantly higher expressed in PBMCs of patients in advanced stages than in healthy controls (ANOVA, p < 0.05) and IDO1+ macrophages were more abundant in intratumoural areas than peritumoural (t test, p < 0.001). IDO1 expression in PBMCs was significantly correlated with IDO1 activity in serum (SRC, p < 0.05). IDO1 activity was significantly higher in patients with LNMs (t test, p < 0.01).All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients.
000181140 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000181140 542__ $$2Crossref$$i2022-08-13$$uhttps://creativecommons.org/licenses/by/4.0
000181140 542__ $$2Crossref$$i2022-08-13$$uhttps://creativecommons.org/licenses/by/4.0
000181140 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181140 650_7 $$2Other$$aIDO
000181140 650_7 $$2Other$$aImmunotherapy
000181140 650_7 $$2Other$$aMacrophage
000181140 650_7 $$2Other$$aOral squamous cell carcinoma (OSCC)
000181140 650_7 $$2Other$$aTumour microenvironment
000181140 7001_ $$aRadermacher, Anne$$b1
000181140 7001_ $$aFehrenz, Michael$$b2
000181140 7001_ $$aBellin, Tamara$$b3
000181140 7001_ $$aAlansary, Dalia$$b4
000181140 7001_ $$aWartenberg, Philipp$$b5
000181140 7001_ $$aBoehm, Ulrich$$b6
000181140 7001_ $$aWagner, Mathias$$b7
000181140 7001_ $$aScheller, Anja$$b8
000181140 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b9$$udkfz
000181140 7001_ $$aMoratin, Julius$$b10
000181140 7001_ $$aFreudlsperger, Christian$$b11
000181140 7001_ $$aHoffmann, Jürgen$$b12
000181140 7001_ $$aThurner, Lorenz$$b13
000181140 7001_ $$aRoemer, Klaus$$b14
000181140 7001_ $$aFreier, Kolja$$b15
000181140 7001_ $$aHorn, Dominik$$b16
000181140 77318 $$2Crossref$$3journal-article$$a10.1007/s00432-022-04277-7$$bSpringer Science and Business Media LLC$$d2022-08-13$$tJournal of Cancer Research and Clinical Oncology$$x0171-5216$$y2022
000181140 773__ $$0PERI:(DE-600)1459285-X$$a10.1007/s00432-022-04277-7$$n7$$p3623-3635$$tJournal of cancer research and clinical oncology$$v149$$x0171-5216$$y2023
000181140 909CO $$ooai:inrepo02.dkfz.de:181140$$pVDB
000181140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000181140 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000181140 9141_ $$y2022
000181140 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER RES CLIN : 2022$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000181140 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000181140 9201_ $$0I:(DE-He78)E221-20160331$$kE221$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000181140 980__ $$ajournal
000181140 980__ $$aVDB
000181140 980__ $$aI:(DE-He78)E221-20160331
000181140 980__ $$aUNRESTRICTED
000181140 999C5 $$1AM Alves$$2Crossref$$9-- missing cx lookup --$$a10.1111/jop.12643$$p460 -$$tJ Oral Pathol Med$$uAlves AM, Diel L, Lamers M (2018) Macrophages and prognosis of oral squamous cell carcinoma: a systemic review. J Oral Pathol Med 47:460–467$$v47$$y2018
000181140 999C5 $$1AA Badawy$$2Crossref$$9-- missing cx lookup --$$a10.1177/1178646919868978$$p117864691986897 -$$tInt J Tryptophan Res$$uBadawy AA, Guillemin G (2019) The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res 12:1178646919868978. https://doi.org/10.1177/1178646919868978$$v12$$y2019
000181140 999C5 $$1A Ben-Haj-Ayed$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.imlet.2015.11.012$$p23 -$$tImmunol Lett$$uBen-Haj-Ayed A, Moussa A, Ghedira R, Gabbouj S, Miled S, Bouzid N, Tebra-Mrad S, Bouaouina N, Chouchane L, Zakhama A, Hassen E (2016) Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma. Immunol Lett 169:23–32. https://doi.org/10.1016/j.imlet.2015.11.012$$v169$$y2016
000181140 999C5 $$1S Blatt$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jcms.2017.01.033$$p722 -$$tJ Craniomaxillofac Surg$$uBlatt S, Krüger M, Ziebart T, Sagheb K, Schiegnitz E, Goetze E, Al-Nawas B, Pabst AM (2017) Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Craniomaxillofac Surg 45:722–730. https://doi.org/10.1016/j.jcms.2017.01.033$$v45$$y2017
000181140 999C5 $$1F Bray$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2017.01.011$$p167 -$$tEur J Cancer$$uBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167–182. https://doi.org/10.1016/j.ejca.2017.01.011$$v76$$y2017
000181140 999C5 $$1L Brochez$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2017.01.011$$p167 -$$tEur J Cancer$$uBrochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167–182. https://doi.org/10.1016/j.ejca.2017.01.011$$v76$$y2017
000181140 999C5 $$1T Chanmee$$2Crossref$$9-- missing cx lookup --$$a10.3390/cancers6031670$$p1670 -$$tCancers$$uChanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6:1670–1690. https://doi.org/10.3390/cancers6031670$$v6$$y2014
000181140 999C5 $$1I Chevolet$$2Crossref$$9-- missing cx lookup --$$a10.4161/2162402X.2014.982382$$tOncoimmunology$$uChevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L (2015) Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology 4:e982382. https://doi.org/10.4161/2162402X.2014.982382$$v4$$y2015
000181140 999C5 $$1JY Choe$$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2407-14-335$$p335 -$$tBMC Cancer$$uChoe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, Oh S, Kim JE (2014) Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 14:335. https://doi.org/10.1186/1471-2407-14-335$$v14$$y2014
000181140 999C5 $$1OR Colegio$$2Crossref$$9-- missing cx lookup --$$a10.1038/nature13490$$p559 -$$tNature$$uColegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:559–563. https://doi.org/10.1038/nature13490$$v513$$y2014
000181140 999C5 $$1P Economopoulou$$2Crossref$$9-- missing cx lookup --$$a10.1136/esmoopen-2019-000646$$tESMO Open$$uEconomopoulou P, Kladi-Skandali A, Strati A, Koytsodontis G, Kirodimos E, Giotakis E, Maragoudakis P, Gagari E, Maratou E, Dimitriadis G, Kotsantis I, Vagia E, Anastasiou M, Gkotzamanidou M, Kavourakis G, Lianidou E, Psyrri A (2020) Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. ESMO Open 5:e000646. https://doi.org/10.1136/esmoopen-2019-000646$$v5$$y2020
000181140 999C5 $$1L Ferdinande$$2Crossref$$9-- missing cx lookup --$$a10.1038/bjc.2011.513$$p141 -$$tBr J Cancer$$uFerdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I, Cuvelier CA, Demetter P (2012) Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 106:141–147. https://doi.org/10.1038/bjc.2011.513$$v106$$y2012
000181140 999C5 $$1K Freier$$2Crossref$$uFreier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, Lichter P, Hofele C (2003) Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63:1179–1182$$y2003
000181140 999C5 $$1RM Giusti$$2Crossref$$uGiusti RM, Maloney EM, Hanchard B, Morgan OS, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A (1996) Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 5:699–704$$y1996
000181140 999C5 $$1Global cancer statistics$$2Crossref$$9-- missing cx lookup --$$a10.3322/caac.21492$$p394 -$$tCA Cancer J Clin$$uGlobal cancer statistics (2018) (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492$$v68$$y2018
000181140 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3389/fimmu.2020.00120 10.1111/jop.12643$$uHerrera-Rios D, Mughal SS, Teuber-Hanselmann S, Pierscianek D, Sucker A, Jansen P, Schimming T, Klode J, Reifenberger J, Felsberg J, Keyvani K, Brors B, Sure U, Reifenberger G, Schadendorf D, Helfrich I (2020) Macrophages/microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brain. Front Immunol 11:120. https://doi.org/10.3389/fimmu.2020.00120. https://doi.org/10.1111/jop.12643
000181140 999C5 $$1A Huang$$2Crossref$$9-- missing cx lookup --$$a10.1038/sj.bjc.6600336$$p1691 -$$tBr J Cancer$$uHuang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86:1691–1696. https://doi.org/10.1038/sj.bjc.6600336$$v86$$y2002
000181140 999C5 $$1T Inaba$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ygyno.2009.07.015$$p185 -$$tGynecol Oncol$$uInaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F (2009) Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115:185–192. https://doi.org/10.1016/j.ygyno.2009.07.015$$v115$$y2009
000181140 999C5 $$1T Ishio$$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1440-1746.2003.03259.x$$p319 -$$tJ Gastroenterol Hepatol$$uIshio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S (2004) Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 19:319–326. https://doi.org/10.1111/j.1440-1746.2003.03259.x$$v19$$y2004
000181140 999C5 $$1JP Kühn$$2Crossref$$9-- missing cx lookup --$$a10.3390/cancers13184730$$p4730 -$$tCancers (basel)$$uKühn JP, Schmid W, Körner S, Bochen F, Wemmert S, Rimbach H, Smola S, Radosa JC, Wagner M, Morris LGT, Bozzato V, Bozzato A, Schick B, Linxweiler M (2021) HPV status as prognostic biomarker in head and neck cancer-which method fits the best for outcome prediction? Cancers (basel) 13:4730. https://doi.org/10.3390/cancers13184730$$v13$$y2021
000181140 999C5 $$1K Laimer$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.oraloncology.2011.03.007$$p352 -$$tOral Oncol$$uLaimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47:352–357. https://doi.org/10.1016/j.oraloncology.2011.03.007$$v47$$y2011
000181140 999C5 $$1M Linxweiler$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncy.21512$$p219 -$$tCancer Cytopathol$$uLinxweiler M, Bochen F, Wemmert S, Lerner C, Hasenfus A, Bohle RM, Al-Kadah B, Takacs ZF, Smola S, Schick B (2015) Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer. Cancer Cytopathol 123:219–229. https://doi.org/10.1002/cncy.21512$$v123$$y2015
000181140 999C5 $$1GV Long$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(19)30274-8$$p1083 -$$tLancet Oncol$$uLong GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:1083–1097. https://doi.org/10.1016/S1470-2045(19)30274-8$$v20$$y2019
000181140 999C5 $$1AW MacFarlane 4th$$2Crossref$$9-- missing cx lookup --$$a10.1158/2326-6066.CIR-13-0133$$p320 -$$tCancer Immunol Res$$uMacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2:320–331. https://doi.org/10.1158/2326-6066.CIR-13-0133$$v2$$y2014
000181140 999C5 $$1M Mandarano$$2Crossref$$9-- missing cx lookup --$$a10.3390/ijms22094403$$p4403 -$$tInt J Mol Sci$$uMandarano M, Orecchini E, Bellezza G, Vannucci J, Ludovini V, Baglivo S, Tofanetti FR, Chiari R, Loreti E, Puma F, Sidoni A, Belladonna ML (2021) Kynurenine/tryptophan ratio as a potential blood-based biomarker in non-small cell lung cancer. Int J Mol Sci 22:4403. https://doi.org/10.3390/ijms22094403$$v22$$y2021
000181140 999C5 $$1B Marcus$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.20701$$p2779 -$$tCancer$$uMarcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD, Teknos TN (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101:2779–2787. https://doi.org/10.1002/cncr.20701$$v101$$y2004
000181140 999C5 $$1JC Mbongue$$2Crossref$$9-- missing cx lookup --$$a10.3390/vaccines3030703$$p703 -$$tVaccines$$uMbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH (2015) The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 3:703–729. https://doi.org/10.3390/vaccines3030703$$v3$$y2015
000181140 999C5 $$1AL Mellor$$2Crossref$$9-- missing cx lookup --$$a10.1038/nri1457$$p762 -$$tNat Rev Immunol$$uMellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774. https://doi.org/10.1038/nri1457$$v4$$y2004
000181140 999C5 $$1AL Mellor$$2Crossref$$9-- missing cx lookup --$$a10.1038/83183$$p64 -$$tNat Immunol$$uMellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64–68. https://doi.org/10.1038/83183$$v2$$y2001
000181140 999C5 $$1CD Mills$$2Crossref$$9-- missing cx lookup --$$a10.4049/jimmunol.164.12.6166$$p6166 -$$tJ Immunol$$uMills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173. https://doi.org/10.4049/jimmunol.164.12.6166$$v164$$y2000
000181140 999C5 $$1K Minami$$2Crossref$$9-- missing cx lookup --$$a10.3892/etm.2018.5959$$p4465 -$$tExp Ther Med$$uMinami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S (2018) Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 15:4465–4476. https://doi.org/10.3892/etm.2018.5959$$v15$$y2018
000181140 999C5 $$1J Moratin$$2Crossref$$9-- missing cx lookup --$$a10.1002/hed.25713$$p2484 -$$tHead Neck$$uMoratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, Hess J, Horn D (2019) Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck 41:2484–2491. https://doi.org/10.1002/hed.25713$$v41$$y2019
000181140 999C5 $$1DH Munn$$2Crossref$$9-- missing cx lookup --$$a10.1084/jem.189.9.1363$$p1363 -$$tJ Exp Med$$uMunn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363–1372. https://doi.org/10.1084/jem.189.9.1363$$v189$$y1999
000181140 999C5 $$1DH Munn$$2Crossref$$9-- missing cx lookup --$$a10.1126/science.1073514$$p1867 -$$tScience$$uMunn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870. https://doi.org/10.1126/science.1073514$$v297$$y2002
000181140 999C5 $$1DH Munn$$2Crossref$$9-- missing cx lookup --$$a10.4049/jimmunol.172.7.4100$$p4100 -$$tJ Immunol$$uMunn DH, Sharma MD, Mellor AL (2004) Ligation of B7–1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100–4110. https://doi.org/10.4049/jimmunol.172.7.4100$$v172$$y2004
000181140 999C5 $$1T Ohashi$$2Crossref$$9-- missing cx lookup --$$a10.1111/cas.13244$$p1128 -$$tCancer Sci$$uOhashi T, Aoki M, Tomita H, Akazawa T, Sato K, Kuze B, Mizuta K, Hara A, Nagaoka H, Inoue N, Ito Y (2017) M2-like macrophage polarization in high lactic acid-producing head and neck cancer. Cancer Sci 108:1128–1134. https://doi.org/10.1111/cas.13244$$v108$$y2017
000181140 999C5 $$1Y Pan$$2Crossref$$9-- missing cx lookup --$$a10.3389/fimmu.2020.583084$$tFront Immunol$$uPan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084. https://doi.org/10.3389/fimmu.2020.583084$$v11$$y2020
000181140 999C5 $$1R Riesenberg$$2Crossref$$9-- missing cx lookup --$$a10.1158/1078-0432.CCR-07-0942$$p6993 -$$tClin Cancer Res$$uRiesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W (2007) Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 13:6993–7002. https://doi.org/10.1158/1078-0432.CCR-07-0942$$v13$$y2007
000181140 999C5 $$1B Ruffell$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ccell.2015.02.015$$p462 -$$tCancer Cell$$uRuffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472. https://doi.org/10.1016/j.ccell.2015.02.015$$v27$$y2015
000181140 999C5 $$1GN Scott$$2Crossref$$9-- missing cx lookup --$$a10.4049/jimmunol.0804328$$p7509 -$$tJ Immunol$$uScott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182:7509–7517. https://doi.org/10.4049/jimmunol.0804328$$v182$$y2009
000181140 999C5 $$1M Seppälä$$2Crossref$$9-- missing cx lookup --$$a10.3109/00016489.2016.1152631$$p729 -$$tActa Otolaryngol$$uSeppälä M, Halme E, Tiilikainen L, Luukkainen A, Laranne J, Rautiainen M, Huhtala H, Paavonen T, Toppila-Salmi S (2016) The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. Acta Otolaryngol 136:729–735. https://doi.org/10.3109/00016489.2016.1152631$$v136$$y2016
000181140 999C5 $$1Y Suzuki$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.lungcan.2009.05.001$$p361 -$$tLung Cancer$$uSuzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365. https://doi.org/10.1016/j.lungcan.2009.05.001$$v67$$y2010
000181140 999C5 $$1P Tattevin$$2Crossref$$9-- missing cx lookup --$$a10.1086/650996$$p956 -$$tJ Infect Dis$$uTattevin P, Monnier D, Tribut O, Dulong J, Bescher N, Mourcin F, Uhel F, Le Tulzo Y, Tarte K (2010) Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis 201:956–966. https://doi.org/10.1086/650996$$v201$$y2010
000181140 999C5 $$1MW Taylor$$2Crossref$$9-- missing cx lookup --$$a10.1096/fasebj.5.11.1907934$$p2516 -$$tFASEB J$$uTaylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516–2522$$v5$$y1991
000181140 999C5 $$1I Théate$$2Crossref$$9-- missing cx lookup --$$a10.1158/2326-6066.CIR-14-0137$$p161 -$$tCancer Immunol Res$$uThéate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ (2015) Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3:161–172. https://doi.org/10.1158/2326-6066.CIR-14-0137$$v3$$y2015
000181140 999C5 $$1C Tripathi$$2Crossref$$9-- missing cx lookup --$$a10.18632/oncotarget.2110$$p5350 -$$tOncotarget$$uTripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, Kaur H, Bhatt ML, Bhadauria S (2014) Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5:5350–5368. https://doi.org/10.18632/oncotarget.2110$$v5$$y2014
000181140 999C5 $$1S Valastyan$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.cell.2011.09.024$$p275 -$$tCell$$uValastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292. https://doi.org/10.1016/j.cell.2011.09.024$$v147$$y2011
000181140 999C5 $$1F Wehrhan$$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2407-14-522$$p522 -$$tBMC Cancer$$uWehrhan F, Büttner-Herold M, Hyckel P, Moebius P, Preidl R, Distel L, Ries J, Amann K, Schmitt C, Neukam FW, Weber M (2014) Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes—an immunohistochemical study. BMC Cancer 14:522. https://doi.org/10.1186/1471-2407-14-522$$v14$$y2014
000181140 999C5 $$1K Wu$$2Crossref$$9-- missing cx lookup --$$a10.3389/fimmu.2020.01731$$p1731 -$$tFront Immunol$$uWu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D (2020) Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol 11:1731. https://doi.org/10.3389/fimmu.2020.01731$$v11$$y2020
000181140 999C5 $$1Y Yao$$2Crossref$$9-- missing cx lookup --$$a10.1186/s13046-021-01847-4$$p60 -$$tJ Exp Clin Cancer Res$$uYao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q (2021) What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res 40:60. https://doi.org/10.1186/s13046-021-01847-4$$v40$$y2021
000181140 999C5 $$1J Ye$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00428-012-1340-x$$p73 -$$tVirchows Arch$$uYe J, Liu H, Hu Y, Li P, Zhang G, Li Y (2013) Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch 462:73–81. https://doi.org/10.1007/s00428-012-1340-x$$v462$$y2013
000181140 999C5 $$1QH Zhou$$2Crossref$$9-- missing cx lookup --$$a10.1002/cac2.12001$$p3 -$$tCancer Commun (lond)$$uZhou QH, Han H, Lu JB, Liu TY, Huang KB, Deng CZ, Li ZS, Chen JP, Yao K, Qin ZK, Liu ZW, Li YH, Guo SJ, Ye YL, Zhou FJ, Liu RY (2020) Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Cancer Commun (lond) 40:3–15. https://doi.org/10.1002/cac2.12001$$v40$$y2020